Skip to main content
Past Event

Brookings Roundtable on Active Medical Product Surveillance: Overview of FDA’s Sentinel Initiative

Past Event

Brookings Roundtable on Active Medical Product Surveillance: Overview of FDA’s Sentinel Initiative

It has been three years since FDA launched the Sentinel Initiative and, since then, FDA has made significant progress. On September 7, the Engelberg Center hosted the first of the three-part Sentinel Initiative 101 Webinar Series, “Overview of FDA’s Sentinel Initiative” to review ongoing activities and accomplishments. The roundtable featured a presentation from Dr. Judy Racoosin, Sentinel Initiative Scientific Lead, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration.

Dr. Racoosin’s presentation provided a high-level review of the Sentinel Initiative’s scope and achievements including:

  • FDA’s 3-year vision for the Sentinel Initiative
  • A brief overview of the role of the Mini-Sentinel pilot, the Observational Medical Outcomes Partnership, the Federal Partners Collaboration, and the Brookings Institution cooperative agreement
  • Next steps for the Sentinel Initiative

Subsequent webinars in this series will provide a more in-depth overview of these pilot activities.

Agenda

Welcome and Introduction

Mark B. McClellan

Former Brookings Expert

Mark McClellan is a senior fellow and director of the Health Care Innovation and Value Initiative at Brookings. He has written a number of publications on care delivery reform, physician payment reform, and accountable care implementation in the U.S. and abroad.

Overview of Sentinel Initiative

J

Judy Racoosin

Sentinel Initiative Scientific Lead, Office of Medical Policy, Center for Drug Evaluation and Research

More Information

More

Get a weekly events calendar from Brookings